ROCKVILLE, Md. - Future promise and flexible regulation of autologous cell therapy to treat injuries and to make other structural repairs were twin themes emphasized last week at a meeting of FDA staff gathered to consider the future course of regulation.

FDA officials at the Commissioner's Roundtable For Autologous Cells Manipulated Ex Vivo for Structural Repair (MAS) said they expect that existing regulations will adequately address product safety and efficacy, and appropriate design of